Small Cell Lung Cancer Extensive Stage

Oncology
4
Pipeline Programs
4
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
MHB088C for InjectionPhase 31 trial
Active Trials
NCT06954246RecruitingEst. Apr 2028
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
AtezolizumabPhase 2Monoclonal Antibody2 trials
Active Trials
NCT04462276Completed68Est. Sep 2024
NCT03158389Completed228Est. Feb 2023
DS
Daiichi SankyoChina - Shanghai
1 program
1
GocatamigPhase 1/21 trial
Active Trials
NCT07227597Recruiting170Est. Nov 2030
InxMed
InxMedChina - Beijing
1 program
1
IN10018Phase 1/21 trial
Active Trials
NCT06030258Recruiting120Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Qilu PharmaceuticalMHB088C for Injection
Heidelberg PharmaAtezolizumab
Daiichi SankyoGocatamig
InxMedIN10018
Heidelberg PharmaAtezolizumab

Clinical Trials (5)

Total enrollment: 586 patients across 5 trials

NCT06954246Qilu PharmaceuticalMHB088C for Injection

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Start: Jun 2025Est. completion: Apr 2028
Phase 3Recruiting
NCT04462276Heidelberg PharmaAtezolizumab

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

Start: Jul 2020Est. completion: Sep 202468 patients
Phase 2Completed
NCT07227597Daiichi SankyoGocatamig

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Start: Jan 2026Est. completion: Nov 2030170 patients
Phase 1/2Recruiting
NCT06030258InxMedIN10018

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Start: Oct 2023Est. completion: Dec 2025120 patients
Phase 1/2Recruiting
NCT03158389Heidelberg PharmaAtezolizumab

NCT Neuro Master Match - N²M² (NOA-20)

Start: May 2018Est. completion: Feb 2023228 patients
Phase 1/2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
9m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
9m ago

Office Administrator

SystImmune
9m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
20m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
23m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
23m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 586 patients
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)